Pfizer Plans to Seek FDA Nod for COVID-19 Booster Next Month as Delta Spreads

Source: FirstWord

Pfizer’s chief scientific officer Mikael Dolsten indicated Thursday that the company plans to seek an FDA emergency-use authorization next month for a third dose of its COVID-19 vaccine BNT162b2, according to a FirstWord report.

The mRNA-based vaccine, partnered with BioNTech, is currently authorized in the US to be administered as two doses in people as young as 12. However, the companies highlighted initial data from a booster study suggesting that a third shot, given about 6 months after the second, induces neutralization titres against the original virus and Beta variant (B.1.351) that are five to 10 times higher than after the two primary doses.

Read the full article. 


Related Content